DATA NOTE

Electronic health record and genome-wide genetic data in Generation Scotland participants [version 1; peer review: 2 approved, 1 approved with reservations]

Shona M. Kerr 1, Archie Campbell 2, Jonathan Marten 1, Veronique Vitart 1, Andrew M McIntosh 3,4, David J. Porteous 2,5, Caroline Hayward 1

1MRC Human Genetics Unit, University of Edinburgh, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, EH4 2XU, UK
2Generation Scotland, Centre for Genomic and Experimental Medicine, University of Edinburgh, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, EH4 2XU, UK
3Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, EH10 5HF, UK
4Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK
5Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK

Abstract

This article provides the first detailed demonstration of the research value of the Electronic Health Record (EHR) linked to research data in Generation Scotland Scottish Family Health Study (GS:SFHS) participants, together with how to access this data. The structured, coded variables in the routine biochemistry, prescribing and morbidity records, in particular, represent highly valuable phenotypic data for a genomics research resource. Access to a wealth of other specialized datasets, including cancer, mental health and maternity inpatient information, is also possible through the same straightforward and transparent application process.

The EHR linked dataset is a key component of GS:SFHS, a biobank conceived in 1999 for the purpose of studying the genetics of health areas of current and projected public health importance. Over 24,000 adults were recruited from 2006 to 2011, with broad and enduring written informed consent for biomedical research. Consent was obtained from 23,603 participants for GS:SFHS study data to be linked to their Scottish National Health Service (NHS) records, using their Community Health Index number. This identifying number is used for NHS Scotland procedures (registrations, attendances, samples, prescribing and investigations) and allows healthcare records for individuals to be linked across time and location. Here, we describe the NHS EHR dataset on the sub-cohort of 20,032 GS:SFHS participants with consent and mechanism for record linkage plus extensive genetic data. Together with existing study phenotypes, including family history and environmental exposures, such as smoking, the EHR is a rich resource of real world data that can be used in research to characterise...
the health trajectory of participants, available at low cost and a high degree of timeliness, matched to DNA, urine and serum samples and genome-wide genetic information.

Keywords
Electronic Health Record, Data, Biobank, Genotype, Generation Scotland

This article is included in the Generation Scotland gateway.
Introduction

Generation Scotland Scottish Family Health Study (GS:SFHS) is a large, family-based, intensively-phenotyped cohort of volunteers from the general population across Scotland, UK. The median age at recruitment was 47 for males and 48 for females, and the cohort has 99% white ethnicity. The numbers of participants with full phenotype data, genome-wide genotype, consent and mechanism for health record linkage are shown in Figure 1. Research data (baseline and derived subsequent to recruitment) are managed by GS in a study database and routine Electronic Health (EHR) data stored by National Health Service (NHS) Scotland in a national database. To create the EHR research dataset, data on GS:SFHS participants was extracted by the NHS National Services Scotland electronic Data Research and Innovation Service (eDRIS), using the Community Health Index (CHI) number for linkage, then de-identified with a new ID. For research purposes, this data is housed in a secure data centre, e.g. a safe haven. It can be analysed through secure protocols, and then de-identified individual-level study and routine medical data can be brought together for analysis in specific approved research projects (Figure 1). This mechanism is designed to respect the wishes and expectations of the volunteer participants.

The genome-wide data in GS:SFHS has been used in a large number of research projects across a wide range of study phenotypes that have generated over 100 publications. Three papers have to date been published on research that used record linkage in GS:SFHS. The first was on the impact of parental diabetes on offspring health, in 2015. The second (and first example of NHS record linkage for genetic research in GS:SFHS) involved the identification of over 200 cases with atrial fibrillation and matched controls by linkage to hospital episode (Scottish Morbidity Record, SMR01) data (based on International Classification of Diseases (ICD-10) codes), as part of the AFGen Consortium. The third used linkage to NHS biochemistry data in a genome-wide association study (GWAS) of both directly measured and imputed genotypes.

Extensive and detailed phenotyping, including longitudinal biochemistry data, is of considerable utility in understanding underlying biological or disease mechanisms. However, this data can be difficult and expensive to obtain directly, as laboratory measures require different assays and the quantity of donated samples (e.g. serum, plasma) is finite in a biobank such as GS:SFHS. Collecting longitudinal samples and data in a research setting requires ongoing re-contact with study participants, which is both costly and time-consuming. Access to routine EHR data is therefore of great value in genetic research across broad-based medical specialities, as exemplified by the Electronic Medical Records and Genomics (eMERGE) network in the USA, and the UK Biobank.

Methods

GS:SFHS probands were first approached through their General Practitioner (GP) using the CHI database, which has a unique number for each individual in >96% of the Scottish population registered with a GP. Those who indicated that they and one or more of their relatives were considering participation were sent an information leaflet, a consent form and a questionnaire. The details of this recruitment of 24,084 participants to GS:SFHS have been described previously. DNA was extracted from the blood or saliva of participants, and samples were genotyped using a genome-wide SNP array (Illumina OmniExpressExome). A subset of participants was selected for genotyping, consisting of those individuals who were born in the UK, had Caucasian ethnicity, had full baseline phenotype data available from a visit to a GS:SFHS research clinic in Aberdeen, Dundee, Glasgow or Perth, and had consented for their data to be linked to their NHS records. The total number of participants genotyped was 20,128, of which 20,032 passed additional genetic quality control filtering.

Scottland has some of the most comprehensive health service data in the world. Few other countries can lay claim to national indexed data of such high quality and consistency. Timelines for individual administrative datasets useful in research can be accessed, with (for example) General Acute/Inpatient Scottish Morbidity Record (SMR01) data available from 1981. Coverage dates for biochemistry EHRs vary regionally across Scotland due to different dates of implementing storage of records in electronic format across the NHS Area Health Boards. Records in NHS Greater Glasgow and Clyde are available from May 2006 onwards, while some NHS Tayside records (covering the Dundee and Perth GS:SFHS recruitment areas) go back as far as 1988. Data can therefore be accessed for most participants from well before the period of recruitment to the GS:SFHS cohort (2006–2011) and subsequent to participation in the study, up to within a few months of the date of a data release. The resource includes contemporary measures that reflect current tests and treatments. Longitudinal research is therefore feasible, with mechanisms also in place for re-contact of GS participants for targeted follow-up, including recall-by-genotype studies, enabling detailed research on chronic conditions and long-term outcomes.

Dataset validation

The GS phenotype, genotype and imputed data have been subject to extensive quality control and are research ready. The EHR biochemistry data was generated in accredited NHS laboratories for clinical use, therefore the measures are accurate, with internal and external quality control and quality assurance processes in place for all tests and investigations (SCI-Store). Efforts have also been made to map legacy local test codes from clinical biochemistry laboratories to the Read Clinical Classification (Read Codes). Over time assay methods, instrumentation and automation protocols will have changed, but outputs have to show consistency for clinical diagnostic purposes. An NHS Data Quality Assurance team is responsible for ensuring Scottish Morbidity Record (SMR) datasets are accurate, consistent and comparable across time and between sources.

The data available in the EHR in Scotland is extensive, covering both health and social domains, e.g. the Scottish Index of Multiple Deprivation (see the index). The scope of the GS:SFHS resource is illustrated by showing the numbers of participants with various categories of EHR data available (Figure 2). However, some gaps exist. For example, data from primary care (the Scottish Primary Care Information Resource) may become available for linkage in...
Figure 1. Schematic illustrating the mechanism for research data analyses. The datasets available in Generation Scotland and Electronic Health Records (EHRs) are indicated, with numbers of participants and records. The Manhattan plot displays the results of a genome-wide association analysis (GWAS) using genotyped SNPs and EHR-derived serum urate measurements, as an example of how the datasets can be used together in genetic research by approved researchers. The single highest serum urate reading was taken for each participant, with covariates and methods for accounting for relatedness as previously described. The $-\log_{10}(P\text{-value})$ is plotted on the y-axis, and chromosomal location is plotted on the x-axis. The genome-wide significance threshold accounting for multiple testing ($p\text{-value} < 5 \times 10^{-8}$) is indicated by a red line, while suggestive significance ($p\text{-value} < 10^{-5}$) is indicated by a blue line.
future. This would be particularly useful for research on conditions like dementia where much of the health service contact is with GPs.

Another limitation is that any features of illness that occur to participants outside NHS Scotland will not be documented. However, the availability of GS:SFHS study data that was collected at recruitment, together with the range of different types of data available longitudinally in the EHR, mean that (for example) accurate classification of cases and controls can be achieved.

An illustration of how the genetic and EHR data in GS:SFHS can be used is in examining the psychiatric history of cases of major depressive disorder (MDD) and controls using record linkage to the SMR (Outpatient and Mental Health Inpatient datasets) and prescription data (for history of antidepressants). This information has been used in haplotype association analyses of MDD, stratification of MDD into genetic subgroups and genome-wide meta-analyses of stratified depression. Data science has great potential as a catalyst for improved mental health recognition, understanding, support and outcomes.

Validation of the laboratory EHR data was provided by a GWAS of serum urate in the Tayside regional subset of the cohort. Uric acid is a medically relevant phenotype measure, with high levels leading to the formation of monosodium urate crystals that can cause gout. Hyperuricaemia has additionally been associated with a variety of diseases including type 2 diabetes, hypertension and cardiovascular disease, while hypouricaemia has been linked to neurodegenerative disorders, including Parkinson’s and Alzheimer’s disease. GWAS of uric acid was performed using EHR-derived measures from 2,077 individuals and shows the strong signal in the SLC2A9 gene, previously reported using data gathered specifically for research. This positive control confirmed that the EHR-derived biochemistry data can be suitable for population-based analyses, despite being collected for clinical purposes. The initial GWAS has now been extended into the Glasgow regional subset of the cohort (Figure 1), increasing the number of individuals with both genotype data and at least one uric acid measurement to 3,160, within the total of 19,233 participants where biochemistry data can be accessed (Figure 2).

Summary statistics for ~600,000 single nucleotide polymorphisms are available, and these results are being incorporated into a meta-analysis consortium analysis due to be submitted by the end of 2017.

Table 1 lists the 30 most frequently collected serum biochemistry measures, with the number of unique participants and total number of their tests shown. The test with the highest number of measures recorded (in unique participants) is creatinine, with 206,498 records...
Table 1. The 30 most frequently collected serum biochemistry measures, by number of unique participants. The description of each measure, local code, Read Code, total number of records, number of unique participants and unique participants with genotype data are shown. Totals are for data collected from 2006 to 2016 on participants aged 18 or over.

<table>
<thead>
<tr>
<th>Description</th>
<th>Local code</th>
<th>Read Code</th>
<th>Total records</th>
<th>Unique IDs</th>
<th>Unique IDs with Genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine</td>
<td>CR</td>
<td>44J3.</td>
<td>206498</td>
<td>17393</td>
<td>16069</td>
</tr>
<tr>
<td>Sodium</td>
<td>NA</td>
<td>44I5.</td>
<td>205738</td>
<td>17387</td>
<td>16056</td>
</tr>
<tr>
<td>Urea</td>
<td>UREA</td>
<td>44J9.</td>
<td>193348</td>
<td>17355</td>
<td>16038</td>
</tr>
<tr>
<td>Potassium</td>
<td>KA</td>
<td>44I4.</td>
<td>201746</td>
<td>17315</td>
<td>15995</td>
</tr>
<tr>
<td>eGFR</td>
<td>eGFR</td>
<td>451E.</td>
<td>195396</td>
<td>17101</td>
<td>15885</td>
</tr>
<tr>
<td>Glucose</td>
<td>GL</td>
<td>44g..</td>
<td>89325</td>
<td>16604</td>
<td>15424</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>AP</td>
<td>44F..</td>
<td>224274</td>
<td>15564</td>
<td>14148</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>BI</td>
<td>44EC.</td>
<td>148662</td>
<td>15220</td>
<td>14088</td>
</tr>
<tr>
<td>Albumin</td>
<td>AL</td>
<td>44M4.</td>
<td>225920</td>
<td>15163</td>
<td>14107</td>
</tr>
<tr>
<td>Total Cholesterol</td>
<td>CHO</td>
<td>44P..</td>
<td>72951</td>
<td>15106</td>
<td>14187</td>
</tr>
<tr>
<td>HDL Cholesterol</td>
<td>HDL</td>
<td>44P5.</td>
<td>68357</td>
<td>14748</td>
<td>13855</td>
</tr>
<tr>
<td>ALT/SGPT</td>
<td>ALT</td>
<td>44G3.</td>
<td>136145</td>
<td>13545</td>
<td>12541</td>
</tr>
<tr>
<td>TSH</td>
<td>TSH</td>
<td>44TW.</td>
<td>60750</td>
<td>13166</td>
<td>12203</td>
</tr>
<tr>
<td>C-Reactive Protein</td>
<td>CRP</td>
<td>44CS.</td>
<td>81382</td>
<td>11807</td>
<td>10938</td>
</tr>
<tr>
<td>Corrected calcium</td>
<td>CC</td>
<td>44IC.</td>
<td>47913</td>
<td>11642</td>
<td>10767</td>
</tr>
<tr>
<td>Calcium</td>
<td>CA</td>
<td>44I8.</td>
<td>67949</td>
<td>11631</td>
<td>10757</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>TRIG</td>
<td>44Q.</td>
<td>34374</td>
<td>8373</td>
<td>7769</td>
</tr>
<tr>
<td>Gamma-Glutamyltransferase</td>
<td>GT</td>
<td>44G9.</td>
<td>38172</td>
<td>7351</td>
<td>6715</td>
</tr>
<tr>
<td>Free Thyroxine</td>
<td>FT4</td>
<td>44V.</td>
<td>26892</td>
<td>7272</td>
<td>6693</td>
</tr>
<tr>
<td>Protein (Total)</td>
<td>TP</td>
<td>44M3.</td>
<td>39303</td>
<td>6925</td>
<td>6341</td>
</tr>
<tr>
<td>Chloride</td>
<td>PCL</td>
<td>44I6.</td>
<td>80031</td>
<td>6749</td>
<td>6191</td>
</tr>
<tr>
<td>Phosphate</td>
<td>PH</td>
<td>44I9.</td>
<td>33796</td>
<td>6360</td>
<td>5825</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>BIC</td>
<td>44I7.</td>
<td>23877</td>
<td>4197</td>
<td>3843</td>
</tr>
<tr>
<td>Creatine kinase</td>
<td>CK</td>
<td>44H.</td>
<td>10614</td>
<td>3907</td>
<td>3623</td>
</tr>
<tr>
<td>Magnesium</td>
<td>MG</td>
<td>44LD.</td>
<td>18331</td>
<td>3794</td>
<td>3470</td>
</tr>
<tr>
<td>Amylase</td>
<td>AMY</td>
<td>44CN.</td>
<td>8856</td>
<td>3498</td>
<td>3222</td>
</tr>
<tr>
<td>Urate</td>
<td>URIC</td>
<td>44K5.</td>
<td>6688</td>
<td>3002</td>
<td>2780</td>
</tr>
<tr>
<td>LDL Cholesterol (calc)</td>
<td>CLDL</td>
<td>44Pl.</td>
<td>15269</td>
<td>3223</td>
<td>2968</td>
</tr>
<tr>
<td>FSH</td>
<td>FSH</td>
<td>443h.</td>
<td>4272</td>
<td>2766</td>
<td>2580</td>
</tr>
<tr>
<td>Transferrin</td>
<td>TRF</td>
<td>44CB.</td>
<td>6255</td>
<td>2734</td>
<td>2507</td>
</tr>
</tbody>
</table>

from 17,393 participants. Urate is relatively low down the list (27th position), but nonetheless enough data is available to yield a highly significant (top hit p-value = 7.29 x 10^-21) GWAS result (Figure 1). This helps to demonstrate the breadth and depth of research that is possible with the biochemistry dataset, only one of many that are available (Figure 2).

Hospital admission, prescription and biochemistry EHRs can be used to infer disease status in individuals after recruitment to the study has concluded, including for diseases that were not part of the initial data collection. One such example is gout, which was not explicitly included in the pre-clinical questionnaire, but with access to EHR data it is possible to ascertain gout status for participants in GS:SFHS. Not all individuals with hyperuricaemia develop gout, which may mean that other factors predispose individuals to a greater or lesser risk of disease progression. Identifying these factors could help inform targeted prevention and personalised management of the disease. The up-to-date status of risk factors
available in GS:SFHS from EHR linkage makes it an excellent resource for a case-to-high-risk-control GWAS. A static study might incorrectly class an individual as a high-risk control simply because they did not develop gout until after data collection had concluded. Here, 420 gout cases have been identified through the use ofurate lowering medication, obtained from the Scottish National Prescribing Information System (PIS)\(^1\). Additional information can be obtained from the GS:SFHS baseline phenotype dataset, including self-reported use of medications and measures such as body mass index. This information, together with the range of risk factors available in the biochemistry, prescribing and morbidity EHR datasets (e.g. gout ICD-10 codes in SMR01), will be used to select risk-matched individuals who have not developed gout for a case-control GWAS of GS:SFHS participants.

**Ethical statement**

GS:SFHS has Research Tissue Bank status from the East of Scotland Research Ethics Service (REC Reference Number: 15/ES/0040). This provides a favourable opinion for a wide range of data and sample uses within medical research. Research that includes access to individual-level EHR data is notified to the Research Ethics Committee by the GS management team on behalf of the researchers, through a notice of substantial amendment.

**Consent**

Only data from those GS:SFHS participants who gave written informed consent for record linkage of their GS:SFHS study data to their medical records are used.

**Data availability**

The study phenotype (cohort profile)\(^2\) and genotype data (both directly typed and imputed to the Haploype Reference Consortium release 1.1 panel)\(^3\) have both been described. A phenotype data dictionary is available and open access GWAS summary statistics can be downloaded.

Non-identifiable information from the GS:SFHS cohort is available to researchers in the UK and to international collaborators through application to the GS Access Committee. GS operates a managed data access process including an online application form, and proposals are reviewed by the GS Access Committee. Summary information to help researchers assess the feasibility and statistical power of a proposed project is available on request by contacting resources@generationscotland.org. For example, the numbers of participants with each biochemistry measure listed, and the total number of measures available per participant, are provided in Table 1. Researchers requesting individual-level EHR data must also submit their proposal to the NHS Public Benefit and Privacy Panel for Health and Social Care.

If access to biochemistry EHR data is part of the proposed research, an additional application to the two data Safe Havens holding this data is required (NHSGGC Safe Haven; and HIC Safe Haven), with a new safe haven workspace created for each project. The biochemistry data was generated as part of routine medical care by the NHS, and only modest cost recovery charges are made to provide access to it for research purposes. This compares favourably with the costs of commissioning new tests on blood, serum or plasma samples. The GS data access process also incurs an administrative cost recovery charge.

Once a proposal has been approved, researchers are provided with pseudo-anonymised data extracts. CHI numbers are replaced by unique study numbers and personal identifying information is removed. Numbers of participant records currently available for each of the main EHR data categories, and the proportion with genome-wide genotype data, are illustrated in Figure 2. The numbers of data points will increase over time as the participants grow older, covering a wide range of clinically relevant outcomes and continuing to extend this rich research resource.

**Competing interests**

No competing interests were disclosed.

**Grant information**

The GS:SFHS DNA samples were genotyped by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, funded by the Medical Research Council UK and the Wellcome Trust ((104036); Wellcome Trust Strategic Award “Stratifying Resilience and Depression Longitudinally” (STRADL)). The Medical Research Council UK provides core funding to the QTL in Health and Disease research programme at the MRC HGU, University of Edinburgh. GS received core support from the Scottish Executive Health Department, Chief Scientist Office [CZD/16/6] and the Scottish Funding Council [HR03006].

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Acknowledgements**

We are grateful to all the families who took part in GS:SFHS, the GPs and the Scottish School of Primary Care for their help in recruiting them, and the entire participant recruitment team. We thank staff at the University of Dundee Health Informatics Centre, NHS Greater Glasgow and Clyde Safe Haven and NHS National Service Scotland eDRIS for their expert assistance with EHR data linkage. The work in this paper uses data provided by patients and collected by the NHS as part of their care and support.

**References**


Susan J. Lindsay
Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

This paper describes linkage of electronic health records to an already well-described genetic and phenotyping resource access to which has proved instrumental in many studies. The strong case for the research advantages of linking electronic health records is made very clearly and interesting examples selected to illustrate the arguments. The paper also addresses important areas that are potential concerns or limitations; for example evidence for the quality of the NHS data and approaches to making data that has been collected in different locations and time-periods comparable are well-described. As well as referring to earlier papers, much of the supporting information on the participant cohort or needed to assess the procedures used and organisation and labelling of the datafiles are briefly referred to in the paper with the detail necessary available via links to other websites. Given the scale and complexity of the resource, I think this is acceptable. The Generation Scotland website, for example, describes access policy, including mechanisms for ensuring data security. Data security measures are also described on the Safe Haven websites. The ethical framework, is outlined in the Ethical Statement and Consent paragraphs and also addressed in several places on the GS website, including in the access policy, and specifically relating to participant confidentiality.

Embedded links to external sites show the excellent informatics and other support context for the GS programme. Indeed, more generally, the paper would be a very good starting point for readers wanting to find out about the field of eHealth research.

In research terms, the paper illustrates that the vision of the co-founders and the work of the GS programme have borne fruit in many ways. Linking the NHS Scotland EHR hugely extends the research potential of the resource and should contribute to “closing the loop” i.e. new treatments and therapies for NHS patients (and patients outside the UK) in the incoming years.

Is the rationale for creating the dataset(s) clearly described?
Yes

Are the protocols appropriate and is the work technically sound?
Yes
Are sufficient details of methods and materials provided to allow replication by others?
Yes

Are the datasets clearly presented in a useable and accessible format?
Partly

*Competing Interests:* The HDBR is funded by the Wellcome Trust and the MRC.

*Reviewer Expertise:* I am co-director of the HDBR, a national research tissue bank, and I have expertise relevant to the paper.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

This paper describes the way in which data linkage has been implemented for Generation Scotland. This is a volunteer cohort of adults with extensive research data including imaging, genomic, -omic and other phenotyping for whom consent was asked for linkage to different types of data available from other sources, most particularly health service records. This builds on the outstanding opportunities that exist in Scotland which has suffered less from fragmentation and barriers to access to appropriate routine data than particularly England. Most provided consent so that there is a rich set of data, being continuously updated but which researchers can seek approval to access at any one time for approved research. The paper describes the data linkage itself in detail, outlining the nature of the datasets and the processes. This is, in of itself, valuable for cohorts elsewhere as these are areas that have been extremely challenging to pursue, even when consent from individuals is present.

Data are available for a decade on these individuals. Much of the data to fully understand the cohort is available in other publications, most notably the International Journal of Epidemiology cohort series. The reader cannot establish from this paper what the provenance of the cohort is in terms of its relationship to the source Scottish population (response rate, known response biases etc) but this is not the purpose of the paper. Perhaps it should not be called a Family Health Study given its likely response biases and the fact it is very unlikely to be fully representative of Scotland’s families, but this is more important for the detail of what kind of research these rich data lend themselves to and what they would not be so well suited to.

The description of how to access looks very good, but it is in the doing that people find out what it’s really like. It might be helpful to consider having a flow chart to illustrate the process, and perhaps have some
case examples (even if only referred to on line) for different types of access taking the reader through the
steps for different types of work.

Some minor comments: data are plural; what is the detail of neonatal inpatient information; some of the
diagrams about actual data could be more informative; relatedness is discussed too briefly; there is no
discussion of limitations.

**Is the rationale for creating the dataset(s) clearly described?**
Yes

**Are the protocols appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and materials provided to allow replication by others?**
Partly

**Are the datasets clearly presented in a useable and accessible format?**
Partly

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.

Reviewer Report 02 October 2017

https://doi.org/10.21956/wellcomeopenres.13644.r26079

© 2017 Brown S. This is an open access peer review report distributed under the terms of the Creative Commons
Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly cited.

Sara J. Brown

Skin Research Group, School of Medicine, University of Dundee, Dundee, UK

Thank you for asking me to review this Data Note describing the valuable resource created through
linkage of electronic health records to research data in the Generation Scotland Scottish Family Health Study.
I answered ‘partly’ to question 3: *Are sufficient details of methods and materials provided to allow replication by others?* because it would be useful to have more detail regarding the inclusion/exclusion criteria for the individuals chosen for participation & selected for genotyping. It would also be helpful to clarify how issues such as changes in the normal range definition of biochemical assays are addressed in these longitudinal datasets?

I answered ‘partly’ to question 4: *Are the datasets clearly presented in a useable and accessible format?* because it would be useful to have:

(a) clarification in the abstract which states ‘the 1st detailed demonstration of the research value….’
although 3 publications have appeared to date.
(b) clarification in the abstract regarding availability/cost/ethical considerations of accessing the data.
(c) clarification in the abstract of the terms ‘registrations, attendances, samples’ in this context.
(d) a section in the main manuscript describing the real-word limitations, perhaps listed in a box or table alongside the many strengths that are already emphasized. It would also be very helpful to compare/contrast the strengths of GS:SFHS alongside other population genetics research resources including UK Biobank and eMERGE.
(e) Figure 1 is nice; please consider adding the number of individuals for whom selection criteria were not met; spelling out the abbreviations in the NHS cylinders; adding to the flow-chart to show how approval is obtained.
(f) the manuscript mentions the availability of environmental data eg smoking but this data is not described further.
(g) the example of urate is useful, however the statement that this is 27th in the top 30 and yet shows a significant result in GWAS reflects in part the strength of a single-effect locus on urate levels so it is not appropriate to use this as a justification for the overall study size.
(h) the statement on data availability ‘…GS:SFHS cohort is available to researchers in the UK and to international collaborators…’ is unclear. Are international groups only able to access the data if they have UK collaborators?
(i) more detail on the future plans for this collection to grow/mature as mentioned in the final paragraph.

I have some minor suggestions to improve the report and its formatting:
(i) The methods stating DNA extraction & genotyping are given before the subset selection; it would be more logical for this information to be first.
(ii) The subtitle ‘Dataset validation’ does not describe what appears in subsequent paragraphs; please add more sub-headings that more correctly match the methods.
(iii) The legend in Fig 2 says the ‘exact numbers’ are shown, but these are for the dark blue bars not the light blue data – please clarify.
(iv) please replace abbreviations/acronyms in Fig 2 with words.
(v) please replace light blue bars replaced with a more vivid colour for visibility.

Is the rationale for creating the dataset(s) clearly described?
Yes

Are the protocols appropriate and is the work technically sound?
Yes

Are sufficient details of methods and materials provided to allow replication by others?
Partly

Are the datasets clearly presented in a useable and accessible format?
Partly

**Competing Interests:** My research is funded by the Wellcome Trust and the Tayside Dermatological Research Charity; I provide consultancy for Concept Life Sciences; I have received honoraria for invited talks at the American Academy for Asthma Allergy and Immunology and the British Association of Dermatologists.
**Reviewer Expertise:** Dermatology; dermatogenetics; genetic epidemiology; next generation sequencing, GWAS

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.